Overview

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Status:
Active, not recruiting

Trial end date:
2021-11-19

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.

Phase:

Phase 2

Details

Lead Sponsor:

Glia, LLC

Collaborator:

ORA, Inc.